Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Bengtsson Bengt Åke 1944) "

Sökning: WFRF:(Bengtsson Bengt Åke 1944)

  • Resultat 1-10 av 63
  • [1]234567Nästa
Sortera/gruppera träfflistan
  • Holmer, Helene, et al. (författare)
  • Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone
  • 2007
  • Ingår i: Journal of Clinical Endocrinology and Metabolism. - : Oxford University Press. - 1945-7197 .- 0021-972X. ; 92:9, s. 3560-3567
  • Tidskriftsartikel (refereegranskat)abstract
    • Context: The impact of long-term GH replacement on cerebrovascular and cardiovascular diseases and diabetes mellitus in hypopituitary patients is unknown. Objective: The incidence of nonfatal stroke and cardiac events, and prevalence of type 2 diabetes mellitus ( T2D) and cardioprotective medication were compared between cohorts of GH-deficient (GHD) patients and population controls. Design and Participants: The incidence of nonfatal stroke and cardiac events was estimated retrospectively from questionnaires in 750 GHD patients and 2314 matched population controls. A prevalence of T2D and cardioprotective medication was recorded at the distribution of questionnaires. Time since first pituitary deficiency to start of GH therapy was 4 and 2 yr, and time on GH therapy was 6 yr for GHD women and men, respectively. Results: Lifelong incidence of nonfatal stroke was tripled in GHD women and doubled in GHD men, but a decline was seen in both genders during periods after first pituitary hormone deficiency and GHD, during which most patients had GH therapy. The lifelong incidence of nonfatal cardiac events declined in GHD men during first pituitary hormone deficiency and GHD periods. GHD women had a higher prevalence of T2D and lipid-lowering medication, whereas GHD men had a higher prevalence of antihypertensive medication. Conclusions: The declined risks of nonfatal stroke in both genders and of nonfatal cardiac events in GHD men during periods on GH replacement may be caused by prescription of cardioprotective drugs and 6-yr GH replacement. GHD women had an increased prevalence of T2D, partly attributed to higher body mass index and lower physical activity.
  • Karason, Kristjan, 1962, et al. (författare)
  • Effect of growth hormone treatment on circulating levels of NT-proBNP in patients with ischemic heart failure.
  • 2020
  • Ingår i: Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. - 1532-2238. ; 55
  • Tidskriftsartikel (refereegranskat)abstract
    • Growth hormone (GH) therapy in heart failure (HF) is controversial. We investigated the cardiovascular effects of GH in patients with chronic HF due to ischemic heart disease.In a double-blind, placebo-controlled trial, we randomly assigned 37 patients (mean age 66 years; 95% male) with ischemic HF (ejection fraction [EF] < 40%) to a 9-month treatment with either recombinant human GH (1.4 mg every other day) or placebo, with subsequent 3-month treatment-free follow-up. The primary outcome was change in left ventricular (LV) end-systolic volume measured by cardiac magnetic resonance (CMR). Secondary outcomes comprised changes in cardiac structure and EF. Prespecified tertiary outcomes included changes in New York Heat Association (NYHA) functional class and quality of life (QoL), as well as levels of insulin-like growth factor-1 (IGF-1) and N-terminal pro-brain natriuretic peptide (NT-proBNP).No changes in cardiac structure or systolic function were identified in either treatment group; nor did GH treatment affect QoL or functional class. In the GH group, circulating levels of IGF-1 doubled from baseline (+105%; p < 0.001) and NT-proBNP levels halved (-48%; p < 0.001) during the treatment period, with subsequently a partial return of both towards baseline levels. No changes in IGF-1 or NT-proBNP were observed in the placebo group at any time during the study.In patients with chronic ischemic HF, nine months of GH treatment was associated with significant increases in levels of IGF-1 and reductions in levels of NT-proBNP, but did not affect cardiac structure, systolic function or functional capacity.
  • Svensson, Johan, 1964, et al. (författare)
  • Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption.
  • 2004
  • Ingår i: Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. - 1096-6374. ; 14:3, s. 207-15
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: The objective was to investigate the effects of 3 years of growth hormone (GH) replacement therapy in GH deficient (GHD) patients in Sweden. DESIGN AND PATIENTS: An open label study in 237 adults with GHD (116 men and 121 women), consecutively enrolled in KIMS (Pfizer's international metabolic database) in Sweden. MEASUREMENTS: QoL and healthcare consumption were determined using questionnaires [QoL-assessment of GHD in Adults (QoL-AGHDA), the psychological general well-being (PGWB) index and the patient life situation form (PLSF)]. RESULTS: The mean starting dose of GH was 0.13 mg/day and the mean maintenance dose was 0.37 mg/day. The mean insulin-like growth factor I (IGF-I) SD score increased from -1.92 at baseline to 0.38 after 3 years. There was a sustained increase in QoL as measured by the QoL-AGHDA and PGWB questionnaires. The number of doctor visits and the number of days in hospital were reduced after 3 years of GH replacement. The number of days of sickleave decreased during the first 2 years of treatment, but returned towards baseline values after 3 years. Leisure-time physical activity and satisfaction with physical activity increased. CONCLUSION: Three years of GH replacement therapy induced a sustained improvement in QoL. Healthcare consumption was reduced, although the reduction in the number of days of sickleave was not statistically significant after 3 years of treatment.
  • Johannsson, Gudmundur, 1960, et al. (författare)
  • Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial.
  • 2002
  • Ingår i: The Journal of clinical endocrinology and metabolism. - 0021-972X. ; 87:5, s. 2046-52
  • Tidskriftsartikel (refereegranskat)abstract
    • Thirty-eight women, aged 25-65 yr, with androgen deficiency due to hypopituitarism were treated with oral dehydroepiandrosterone (DHEA; 30 mg/d if <45 yr of age and 20 mg if > or =45 yr of age) for 6 months in a randomized, placebo-controlled, double blind study, followed by a 6-month open treatment period. The administration of DHEA raised the serum levels of DHEAS to normal age-related reference ranges and increased androstenedione and T to subnormal levels. Androgen effects on skin and/or pubic and/or axillary hair were observed in 84% (32 of 38) of the women after all received 6 months of DHEA treatment. No such effects were observed after the placebo treatment. These effects after 6 months were correlated with the serum levels of DHEAS (r = 0.37; P = 0.03), androstenedione (r = 0.42; P = 0.01), and T (r = 0.37; P = 0.03). The percentages of partners who reported improved alertness, stamina, and initiative by their spouses were 70%, 64%, and 55%, respectively, in the DHEA group and 11%, 6%, and 11%, respectively, in the placebo group (P < 0.05). According to the partners, sexual relations tended to improve compared with placebo (P = 0.06). After 6 months of treatment, increased sexual interest or activity was reported by 50% of the women taking 30 mg DHEA, by none taking 20 mg DHEA, and by two women taking placebo (P = NS). Compared with levels after placebo administration, high density lipoprotein cholesterol and apolipoprotein A-1 levels decreased after DHEA. Serum concentrations of IGF-I, serum markers of bone metabolism, and bone density did not change. In conclusion, oral administration of a low dose of DHEA to adult hypopituitary women induced androgen effects on skin and axillary and pubic hair as well as changes in behavior, with only minor effects on metabolism.
  • Sigurjónsdóttir, Helga A, 1964, et al. (författare)
  • GH effect on enzyme activity of 11betaHSD in abdominal obesity is dependent on treatment duration.
  • 2006
  • Ingår i: European journal of endocrinology / European Federation of Endocrine Societies. - 0804-4643. ; 154:1, s. 69-74
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: In the past years the interaction of GH and 11beta hydroxysteroid dehydrogenase (11betaHSD) in the pathogenesis of central obesity has been suggested. DESIGN: We studied the effects of 9 months of GH treatment on 11betaHSD activity and its relationship with body composition and insulin sensitivity in 30 men with abdominal obesity, aged 48-66 years, in a randomised, double-blind, placebo-controlled trial. METHODS: Urinary steroid profile was used to estimate 11betaHSD type 1 and 2 (11betaHSD1 and 11betaHSD2) activities. Abdominal s.c. and visceral adipose tissues were measured using computed tomography. Glucose disposal rate (GDR) obtained during a euglycaemic-hyperinsulinaemic glucose clamp was used to assess insulin sensitivity. RESULTS: In the GH-treated group the 11betaHSD1 activity decreased transiently after 6 weeks (P < 0.01) whereas 11betaHSD2 increased after 9 months of treatment (P < 0.05). Between 6 weeks and 9 months, GDR increased and visceral fat mass decreased. Changes in 11betaHSD1 correlated with changes in visceral fat mass between baseline and 6 weeks. There were no significant correlations between 11betaHSD1 and 11betaHSD 2 and changes in GDR. DISCUSSION: The study demonstrates that short- and long-term GH treatment has different effects on 11betaHSD1 and 11betaHSD2 activity. Moreover, the data do not support that long-term metabolic effects of GH are mediated through its action on 11betaHSD.
  • Ahlman, Håkan, 1947, et al. (författare)
  • Adrenocortical carcinoma--diagnostic and therapeutical implications.
  • 1993
  • Ingår i: The European journal of surgery = Acta chirurgica. - 1102-4151. ; 159:3, s. 149-58
  • Tidskriftsartikel (refereegranskat)abstract
    • To evaluate the results of treatment of a consecutive series of patients with adrenocortical carcinoma who presented during the six year period 1985 to 1991.
  • Arnestad, J P, et al. (författare)
  • Isolated hyperthermic liver perfusion with cytostatic-containing perfusate activates the complement cascade.
  • 1992
  • Ingår i: The British journal of surgery. - 0007-1323. ; 79:9, s. 948-51
  • Tidskriftsartikel (refereegranskat)abstract
    • Eight patients with advanced liver malignancy undergoing isolated hyperthermic liver perfusion with melphalan and cisplatin were studied with regard to complement activation and formation of anaphylatoxins (C3a and C5a) and terminal C5b-9 complement complexes (TCCs). Blood samples for complement variables (C1-INH, C3, C4, C5, C3a, C5a and TCCs) were taken before surgery, 1 min before the start of perfusion, 1, 2 and 3 h after the start of perfusion, and 24 h after operation. Samples were drawn from the perfusate 1 h after the start of perfusion. Activation of complement was observed during perfusion. Raised plasma concentrations of C3a and TCCs were recorded and high levels of C3a and TCCs were found in the perfusate. In vitro tests indicated that melphalan and cisplatin may activate complement. This activation occurred at 37 and 42 degrees C but was more pronounced at 42 degrees C.
  • Barbosa, Edna J L, 1961, et al. (författare)
  • Extracellular water and blood pressure in adults with growth hormone (GH) deficiency: a genotype-phenotype association study.
  • 2014
  • Ingår i: PloS one. - 1932-6203. ; 9:8
  • Tidskriftsartikel (refereegranskat)abstract
    • Growth hormone deficiency (GHD) in adults is associated with decreased extracellular water volume (ECW). In response to GH replacement therapy (GHRT), ECW increases and blood pressure (BP) reduces or remains unchanged. Our primary aim was to study the association between polymorphisms in genes related to renal tubular function with ECW and BP before and 1 year after GHRT. The ECW measures using bioimpedance analysis (BIA) and bioimpedance spectroscopy (BIS) were validated against a reference method, the sodium bromide dilution method (Br(-)).
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 63
  • [1]234567Nästa
Typ av publikation
tidskriftsartikel (60)
bokkapitel (2)
konferensbidrag (1)
Typ av innehåll
refereegranskat (60)
övrigt vetenskapligt (3)
Bengtsson, Bengt-Åke ... (60)
Johannsson, Gudmundu ... (37)
Svensson, Johan, 196 ... (23)
Bosaeus, Ingvar, 195 ... (13)
Götherström, Galina, ... (11)
Ohlsson, Claes, 1965 (6)
visa fler...
Olsson, Daniel S, 19 ... (6)
Rosén, Thord, 1949 (6)
Nilsson, Anna G, 196 ... (6)
Stibrant Sunnerhagen ... (5)
Lönn, Lars, 1956 (5)
Koranyi, Josef, 1956 (5)
Landin-Wilhelmsen, K ... (4)
Jansson, John-Olov, ... (4)
Barbosa, Edna J L, 1 ... (4)
Svensson, J (3)
Ahlman, Håkan, 1947 (3)
Wängberg, Bo, 1953 (3)
Sjöström, Lars (3)
Lindstedt, Göran, 19 ... (3)
Johannsson, G (3)
Wiklund, Olov, 1943 (3)
Ehrnborg, Christer, ... (3)
Andersson, Björn, 19 ... (3)
Glad, Camilla A M, 1 ... (3)
Boguszewski, Cesar L ... (3)
Naredi, Peter, 1955 (2)
Nilsson, Staffan, 19 ... (2)
Nyström, Helena Fili ... (2)
Nilsson, Ola, 1957 (2)
Bengtsson, Bengt-Ake (2)
Nilsson, M (2)
Dickson, Suzanne L., ... (2)
Svensson, Per-Arne, ... (2)
Tisell, Lars-Eric, 1 ... (2)
Ernest, I (2)
Stenqvist, Ola, 1944 (2)
Caidahl, Kenneth, 19 ... (2)
Erfurth, Eva Marie (2)
Mårin, P (2)
Björntorp, Per, 1931 (2)
Ellegård, Lars, 1958 (2)
Bengtson, Jan Peter (2)
Bengtsson, Anders, 1 ... (2)
Filipsson, Helena, 1 ... (2)
Arnestad, J P (2)
Henriksson, Bengt-Åk ... (2)
Hafström, Lars-Olof, ... (2)
Engstrom, BE (2)
Isaksson, Olle, 1943 (2)
visa färre...
Göteborgs universitet (63)
Karolinska Institutet (3)
Chalmers tekniska högskola (2)
Uppsala universitet (1)
Lunds universitet (1)
Engelska (61)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (28)
Naturvetenskap (1)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy